New portal online about clinical trials worldwide.

A new portal (www.ifpma.org/clinicaltrials), established by the International Federation of Pharmaceutical Manufacturers and Associations, links available online information about clinical trials worldwide.

Comments

Post a Comment

Popular posts from this blog

The Council of the European Union has decided that the European Medicines Agency (EMA) will be relocated to the City of Amsterdam.

Image
The Council of the European Union has decided that the European Medicines Agency (EMA) will be relocated to the City of Amsterdam. The Dutch government proudly welcomes the Agency, its staff and their families to the Netherlands.

We are dedicated to safeguard the continuity of EMA’s important work for all European patients during and after its relocation. Our key objective is to ensure that the Agency can continue to function throughout the relocation process without disruption.

The Dutch government and the Amsterdam Metropolitan Area will begin to initiate the proposed transition activities immediately after the decision on relocation, in close cooperation with EMA.

Watch the movie
Read more

Inflamation and Alzheimer disease

Image
A new study shows that microglia, which are the immune cells of the central nervous system, can "remember" inflammation. This "memory" influences how the cells react to new stimuli and deal with toxic plaque in the brain, a marker of Alzheimer's disease.

The brain's immune cells remember previous inflammation. Microglia, sometimes referred to as "scavenger" cells, "are the primary immune cells of the central nervous system."
As the key player in the brain's immunity, microglia are dispatched to the site of infection or injury, where they fight toxic agents or pathogens and get rid of useless cells.
However, these cells are also known to play a negative role in neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, ischemic stroke, and traumatic brain injuries.
For instance, a recent study showed that when microglia are overactive, they devour toxic plaques along with synapses, which presumably leads…
Read more

spondyloarthritis (SpA), Diclofenac and Myocardial Infarction

Image
NEW YORK (Reuters Health) - Risk of myocardial infarction (MI) is increased in patients with spondyloarthritis (SpA) who use the nonsteroidal anti-inflammatory drug (NSAID) diclofenac but not in those who take naproxen, researchers say.

Dr. Maureen Dubreuil of Boston University School of Medicine and colleagues analyzed 20 years of medical records from the UK's Health Improvement Network for adults ages 18 to 89 with incident ankylosing spondylitis (AS) or psoriatic arthritis (PsA), two forms of SpA. Controls had incident osteoarthritis (OA).

Within each cohort, the team then matched each MI case to four controls without MI.

NSAID use was categorized as (a) current (prescription within 180 days prior to index date); (b) recent (181-365 days) or (c) remote (>365 days).

The daily dosage of diclofenac was 100 mg or more in 92% of individuals with OA, 95% of those with AS, and 92% of those with PsA. The most common daily dosage of naproxen was 1,000 mg (55%); the dose was 1,000…
Read more